Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
Lyft Shares Slide After Weak Q1 Profit Forecast and Surprise 2025 Operating Loss 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year 
Canadian Airlines Suspend Cuba Flights Amid Jet Fuel Shortage and U.S. Sanctions 
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
Alphabet Plans Rare 100-Year Sterling Bond to Fund AI Expansion 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
Macquarie Group Shares Jump as Third-Quarter Trading Conditions Improve Across Key Units 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
Treasury Wine Estates Shares Surge After U.S. Dispute Settlement and Earnings Upgrade 
Trump Administration Plans Chip Tariff Exemptions for Big Tech Amid AI Data Center Push 
LONDON, Jan. 29, 2018 -- GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on 5 February, 2018 its first quarter financial results for the period ending 31 December, 2017. GW will also host a conference call the same day at 4:30 p.m. EST. Conference call information will be provided in the financial results press release. A replay of the call will also be available through the Company's website (www.gwpharm.com) shortly after the call.
About GW Pharmaceuticals plc
Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW, along with its U.S. subsidiary Greenwich Biosciences, is advancing an orphan drug program in the field of childhood epilepsy with a focus on Epidiolex (cannabidiol), for which GW has submitted an NDA to the FDA for the adjunctive treatment of LGS and Dravet syndrome. The Company continues to evaluate Epidiolex in additional epilepsy conditions and currently has ongoing clinical trials in Tuberous Sclerosis Complex and Infantile Spasms. GW commercialized the world’s first plant-derived cannabinoid prescription drug, Sativex® (nabiximols), which is approved for the treatment of spasticity due to multiple sclerosis in numerous countries outside the United States. The Company has a deep pipeline of additional cannabinoid product candidates which includes compounds in Phase 1 and 2 trials for gliobastoma, schizophrenia and epilepsy. For further information, please visit www.gwpharm.com.
Enquiries:
| GW Pharmaceuticals plc | ||
| Stephen Schultz, VP Investor Relations (U.S.) | 917 280 2424 / 401 500 6570 | |
